Valuation: Alto Neuroscience, Inc.

Market Cap 910M 817M 754M 684M 1.28B 86.44B 1.29B 9.04B 3.59B 45.31B 3.42B 3.34B 144B P/E 2026 *
-8.33x
P/E 2027 * -7.72x
Enterprise Value 631M 567M 523M 474M 887M 59.96B 897M 6.27B 2.49B 31.43B 2.37B 2.32B 99.66B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.79%
Yield 2026 *
-
Yield 2027 * -
1 day+4.88%
1 week-5.00%
Current month-9.17%
1 month-12.46%
3 months-16.79%
6 months-4.45%
Current year+30.28%
1 week 21.45
Extreme 21.45
24.29
1 month 21.32
Extreme 21.32
27.42
Current year 13.91
Extreme 13.9121
37.48
1 year 10.2
Extreme 10.2
37.48
3 years 1.6
Extreme 1.6
37.48
5 years 1.6
Extreme 1.6
37.48
10 years 1.6
Extreme 1.6
37.48
Manager TitleAgeSince
Chief Executive Officer 50 25/03/2019
Director of Finance/CFO 38 01/11/2022
Chief Tech/Sci/R&D Officer 61 01/07/2021
Director TitleAgeSince
Chairman 50 25/03/2019
Director/Board Member 47 01/04/2022
Director/Board Member 67 18/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 A Exercice

Chief Financial Officer

110,000 0.2803%
9/30/26 A Exercice

Chief Financial Officer

72,168 0.1839%
5/27/26 A Free

Director

26,000 0.0814%
Change 5-day change 1-year change 3-year change Capi.($)
+4.88%-5.00%+89.31% - 910M
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.33%+0.33%+10.16%+78.07% 54.55B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+1.11%+15.18%+60.27%+49.33% 26.7B
+4.03%-6.07%+26.22%-8.12% 23.36B
Average +0.58%-1.57%+50.16%+154.65% 38.13B
Weighted average by Cap. -0.28%-1.28%+43.07%+155.31%

Financials

2026 *2027 *
Net sales - -
Net income -114M -102M -94.14M -85.37M -160M -10.79B -162M -1.13B -448M -5.66B -426M -417M -17.93B -135M -121M -112M -101M -189M -12.81B -192M -1.34B -532M -6.71B -506M -495M -21.29B
Net Debt -279M -250M -231M -210M -392M -26.48B -396M -2.77B -1.1B -13.88B -1.05B -1.02B -44.02B -365M -327M -302M -274M -513M -34.66B -519M -3.63B -1.44B -18.17B -1.37B -1.34B -57.61B
Projected Income Statement - Annual - Alto Neuroscience, Inc.
Logo Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Employees
68
Date Price Change Volume
27/10/26 $23.19 +4.88% 469,255
26/10/26 $22.11 +0.64% 550,065
23/10/26 $21.97 -1.04% 379,247
22/10/26 $22.20 -4.80% 510,817
21/10/26 $23.32 -4.47% 663,459
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Alto Neuroscience, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
23.19USD
Average target price
38.67USD
Spread / Average Target
+66.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alto Neuroscience, Inc.
  1. Stock Market
  2. Stocks
  3. ANRO Stock